Skip to content
Intelligence IAMay 4, 2026Primary Market
Article

EnteroBiotix · £19M · Series Unknown

EnteroBiotix has secured £19 million in funding to support a clinical trial for microbiome-based therapies targeting irritable bowel syndrome. The company is based in Glasgow.

Redaction Data Cube AISource: Unknown
01

Brief source

EnteroBiotix has secured £19 million in funding to support a clinical trial for microbiome-based therapies targeting irritable bowel syndrome. The company is based in Glasgow.